Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III
Structure Therapeutics announced promising results from its ACCESS II clinical program for aleniglipron, an oral GLP-1 receptor agonist, showing weight loss exceeding 15% in higher dose groups. The company highlighted strong efficacy, improving tolerability with optimized dosing strategies, and no significant safety concerns like DILI or QTc prolongation. Following these positive Phase II results, Structure plans to meet with the FDA in Q2 and initiate Phase III trials in the second half of 2026, while also advancing its broader metabolic pipeline.